Imunon Inc (IMNN) - Net Assets
Based on the latest financial reports, Imunon Inc (IMNN) has net assets worth $4.08 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.99 Million) and total liabilities ($4.91 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Imunon Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.08 Million |
| % of Total Assets | 45.41% |
| Annual Growth Rate | -1.65% |
| 5-Year Change | -77.19% |
| 10-Year Change | -79.18% |
| Growth Volatility | 244.38 |
Imunon Inc - Net Assets Trend (1996–2024)
This chart illustrates how Imunon Inc's net assets have evolved over time, based on quarterly financial data. Also explore Imunon Inc total assets for the complete picture of this company's asset base.
Annual Net Assets for Imunon Inc (1996–2024)
The table below shows the annual net assets of Imunon Inc from 1996 to 2024. For live valuation and market cap data, see market cap of Imunon Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $4.24 Million | -68.30% |
| 2023-12-31 | $13.39 Million | -54.35% |
| 2022-12-31 | $29.33 Million | -47.44% |
| 2021-12-31 | $55.80 Million | +199.80% |
| 2020-12-31 | $18.61 Million | +27.83% |
| 2019-12-31 | $14.56 Million | -30.21% |
| 2018-12-31 | $20.86 Million | -21.88% |
| 2017-12-31 | $26.70 Million | +297.04% |
| 2016-12-31 | $6.73 Million | -67.01% |
| 2015-12-31 | $20.39 Million | -37.90% |
| 2014-12-31 | $32.83 Million | +4.13% |
| 2013-12-31 | $31.52 Million | +163.54% |
| 2012-12-31 | $11.96 Million | -54.33% |
| 2011-12-31 | $26.19 Million | +672.47% |
| 2010-12-31 | $-4.58 Million | -145.59% |
| 2009-12-31 | $10.04 Million | -49.13% |
| 2008-12-31 | $19.73 Million | -35.64% |
| 2007-12-31 | $30.65 Million | +1057.60% |
| 2006-12-31 | $-3.20 Million | -193.44% |
| 2005-12-31 | $3.43 Million | -71.38% |
| 2004-12-31 | $11.97 Million | -11.02% |
| 2003-12-31 | $13.45 Million | +787.11% |
| 2002-12-31 | $1.52 Million | -43.19% |
| 2001-12-31 | $2.67 Million | -69.41% |
| 2000-12-31 | $8.73 Million | +772.64% |
| 1999-12-31 | $1.00 Million | +154.02% |
| 1998-12-31 | $-1.85 Million | +24.77% |
| 1997-12-31 | $-2.46 Million | -136.42% |
| 1996-12-31 | $6.76 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Imunon Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 39459141100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $145.01K | 3.42% |
| Other Components | $410.90 Million | 9681.28% |
| Total Equity | $4.24 Million | 100.00% |
Imunon Inc Competitors by Market Cap
The table below lists competitors of Imunon Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Great Western Exploration Ltd
AU:GTE
|
$9.54 Million |
|
Adaptimmune Therapeutics Plc
NASDAQ:ADAP
|
$9.54 Million |
|
Nanotech Indonesia Global Tbk PT
JK:NANO
|
$9.54 Million |
|
Manhattan Corporation Ltd
AU:MHC
|
$9.54 Million |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
$9.52 Million |
|
Viking Mines Ltd
AU:VKA
|
$9.52 Million |
|
Ben Tre Pharmaceutical JSC
VN:DBT
|
$9.51 Million |
|
Bhakti Agung Propertindo
JK:BAPI
|
$9.50 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Imunon Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 13,387,642 to 4,244,298, a change of -9,143,344 (-68.3%).
- Net loss of 18,620,242 reduced equity.
- New share issuances of 9,060,438 increased equity.
- Other comprehensive income decreased equity by 60,796.
- Other factors increased equity by 477,256.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-18.62 Million | -438.71% |
| Share Issuances | $9.06 Million | +213.47% |
| Other Comprehensive Income | $-60.80K | -1.43% |
| Other Changes | $477.26K | +11.24% |
| Total Change | $- | -68.30% |
Book Value vs Market Value Analysis
This analysis compares Imunon Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.58x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.00x to 0.58x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-12-31 | $56710.10 | $2.80 | x |
| 1997-12-31 | $-18345.23 | $2.80 | x |
| 1998-12-31 | $-1275.81 | $2.80 | x |
| 1999-12-31 | $4609.36 | $2.80 | x |
| 2000-12-31 | $31077.03 | $2.80 | x |
| 2001-12-31 | $7816.16 | $2.80 | x |
| 2002-12-31 | $3677.32 | $2.80 | x |
| 2003-12-31 | $25039.54 | $2.80 | x |
| 2004-12-31 | $1068.92 | $2.80 | x |
| 2005-12-31 | $3936.85 | $2.80 | x |
| 2006-12-31 | $-3677.50 | $2.80 | x |
| 2007-12-31 | $35202.44 | $2.80 | x |
| 2008-12-31 | $23958.11 | $2.80 | x |
| 2009-12-31 | $11609.59 | $2.80 | x |
| 2010-12-31 | $-4557.30 | $2.80 | x |
| 2011-12-31 | $15435.22 | $2.80 | x |
| 2012-12-31 | $4238.79 | $2.80 | x |
| 2013-12-31 | $6377.47 | $2.80 | x |
| 2014-12-31 | $4868.06 | $2.80 | x |
| 2015-12-31 | $2560.05 | $2.80 | x |
| 2016-12-31 | $709.77 | $2.80 | x |
| 2017-12-31 | $685.03 | $2.80 | x |
| 2018-12-31 | $232.13 | $2.80 | x |
| 2019-12-31 | $130.47 | $2.80 | x |
| 2020-12-31 | $113.93 | $2.80 | x |
| 2021-12-31 | $2011.61 | $2.80 | x |
| 2022-12-31 | $53.55 | $2.80 | x |
| 2023-12-31 | $19.31 | $2.80 | x |
| 2024-12-31 | $4.81 | $2.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Imunon Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -438.71%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.29x
- Recent ROE (-438.71%) is below the historical average (-129.29%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | -28.62% | -2612.59% | 0.01x | 1.38x | $-2.61 Million |
| 1997 | 0.00% | -2516.88% | 0.15x | 0.00x | $-2.81 Million |
| 1998 | 0.00% | -2411.55% | 0.53x | 0.00x | $-4.02 Million |
| 1999 | -240.00% | -2400.00% | 0.06x | 1.60x | $-2.50 Million |
| 2000 | -52.11% | -132959.50% | 0.00x | 1.04x | $-5.42 Million |
| 2001 | -259.37% | 0.00% | 0.00x | 1.11x | $-7.19 Million |
| 2002 | -643.00% | 0.00% | 0.00x | 1.51x | $-9.90 Million |
| 2003 | -98.67% | 0.00% | 0.00x | 1.07x | $-14.62 Million |
| 2004 | -116.83% | -558.01% | 0.15x | 1.42x | $-15.18 Million |
| 2005 | -253.55% | -70.50% | 0.77x | 4.64x | $-9.03 Million |
| 2006 | 0.00% | -67.41% | 0.59x | 0.00x | $-7.26 Million |
| 2007 | 115.33% | 0.00% | 0.00x | 1.27x | $32.28 Million |
| 2008 | -59.75% | -471.45% | 0.11x | 1.20x | $-13.76 Million |
| 2009 | -151.39% | 0.00% | 0.00x | 1.48x | $-16.20 Million |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-18.36 Million |
| 2011 | -88.66% | -1161.13% | 0.06x | 1.25x | $-25.84 Million |
| 2012 | -222.11% | 0.00% | 0.00x | 2.12x | $-27.76 Million |
| 2013 | -26.17% | -1650.27% | 0.01x | 1.45x | $-11.40 Million |
| 2014 | -77.67% | -5098.85% | 0.01x | 2.03x | $-28.78 Million |
| 2015 | -110.18% | -4492.22% | 0.01x | 2.41x | $-24.50 Million |
| 2016 | -327.90% | -4410.75% | 0.02x | 4.59x | $-22.73 Million |
| 2017 | -76.40% | -4080.44% | 0.01x | 1.78x | $-23.07 Million |
| 2018 | -56.96% | -2376.67% | 0.01x | 2.25x | $-13.97 Million |
| 2019 | -115.75% | -3370.31% | 0.01x | 2.63x | $-18.31 Million |
| 2020 | -115.43% | -4296.71% | 0.01x | 2.02x | $-23.34 Million |
| 2021 | -37.22% | -4153.85% | 0.01x | 1.33x | $-26.35 Million |
| 2022 | -122.40% | -7179.65% | 0.01x | 1.50x | $-38.83 Million |
| 2023 | -145.77% | -15611.98% | 0.01x | 1.64x | $-20.85 Million |
| 2024 | -438.71% | 0.00% | 0.00x | 2.29x | $-19.04 Million |
Industry Comparison
This section compares Imunon Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Imunon Inc (IMNN) | $4.08 Million | -28.62% | 1.20x | $9.52 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Imunon Inc
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-2… Read more